Pembrolizumab (Keytruda®), Mdna11
Fallopian Tube Cancer, Cervical Cancer, Ovarian Cancer, Bladder Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Solid Tumor, Gastric Cancer, Clear Cell Renal Cell Carcinoma, Cutaneous Melanoma, Msi-H Cancer, Cancer With A High Tumor Mutational Burden, Solid Tumor, Adult, Skin Cancer, Endometrial Cancer, Esophageal Cancer, Squamous Cell Carcinoma Of Head And Neck, Primary Peritoneal Cancer, Unresectable Solid Tumor, Mucosal Melanoma, Endometrial Carcinoma, Pleural Mesothelioma, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-Squamous, Colorectal Cancer (Msi-H), Msi-H Solid Malignant Tumor, Epithelial Ovarian Carcinoma, Gastroesophageal Junction (Gej) Cancer, Acral Melanoma, Dmmr Solid Malignant Tumor, Dmmr Cancer, Pancreas Adenocarcinoma (Msi-H), Viral Cancer, Cervical Cancers
Recruiting
A Beta-only IL-2 ImmunoTherapY Study
―